From Financial Modeling Prep: 2025-05-07 16:17:00

Novo Nordisk (NYSE:NVO) reported a strong first-quarter with a 19% increase in sales, reaching DKK 78.1 billion. Operating profit rose 22% to DKK 38.8 billion, driven by growth in diabetes and obesity care. Despite these positive results, the company lowered its full-year guidance due to challenges in the U.S. GLP-1 market.

The company cited slower-than-anticipated U.S. market dynamics for its GLP-1 treatments as a reason for revising its full-year guidance. Challenges include inventory destocking of Wegovy and increased competition from compounded alternatives. Novo now expects sales growth of 13% to 21% and operating profit growth of 16% to 24% at constant exchange rates for 2025.

At constant exchange rates, Novo Nordisk’s operating profit was up 20%, highlighting strong demand for its blockbuster GLP-1 drugs. The company’s robust growth in diabetes and obesity care contributed to the positive first-quarter results, with sales reaching DKK 78.1 billion. Despite the challenges in the U.S. market, Novo remains optimistic about its future performance.



Read more at Financial Modeling Prep:: Novo Nordisk Shares Climb Despite Guidance Cut as …